Sotatercept治疗肺动脉高压:中枢、血液及外周获益机制
该研究纳入30例肺动脉高压患者,评估24周Sotatercept治疗对运动耐量获益的中枢与外周机制。结果显示Sotatercept改善运动峰值肺动脉/心输出量比、降低肺血管阻力与右心室做功,并通过提高血红蛋白和增加运动心输出量储备增强骨骼肌氧输送与利用。
要点
- Sotatercept改善运动峰值肺动脉/心输出量比及右室-肺动脉耦联。
- Sotatercept通过减少血浆容量升高血红蛋白,降低静息心输出量但增加运动储备。
- Sotatercept增强骨骼肌氧输送与摄取,改善有氧能力。
核心结论
- Sotatercept通过肺血管外多机制改善PAH患者运动耐量,包括血红蛋白升高、右室-肺动脉耦联改善及心输出量储备增加。
研究设计与样本
- 研究纳入30例肺动脉高压患者,平均年龄49.3±13.5岁,女性占70%,接受24周Sotatercept治疗。
- 评估手段包括血容量定量、仰卧位有创心肺运动试验同步超声心动图、单腿运动导管检查及股静脉采血。
- 共进行7次配对血流动力学评估:静息、一氧化氮、被动抬腿、20W运动、峰值运动、重复基线及单腿运动。
主要发现
- 运动峰值肺动脉/心输出量比改善-2.1 mm Hg/L/min(95%CI:-3.1至-1.1,P=0.0003)。
- 肺血管阻力降低-2.6 WU(95%CI:-3.0至-2.2,P<0.0001),平均肺动脉压降低-12.5 mm Hg(95%CI:-13.8至-11.2,P<0.0001)。
- 右心室做功减少-1.1 kg-m/min(95%CI:-1.4至-0.9,P<0.0001),静息与运动时右室-肺动脉耦联均改善。
- 静息血红蛋白升高1.7 g/dL(95%CI:+1.1至+2.2,P<0.0001),与血浆容量减少相关(P<0.0001),红细胞质量无变化(P=0.12)。
- 静息心输出量降低-0.58 L/min(95%CI:-0.85至-0.32,P<0.0001),运动心输出量储备增加+0.74 L/min(95%CI:+0.15至+1.32,P=0.015),与峰值耗氧量相关(r=+0.69,95%CI:+0.43至+0.84,P<0.0001)。
临床怎么用
- Sotatercept治疗PAH的获益不仅来自肺血管扩张,还涉及血液学及外周氧利用机制。
- 临床评估PAH治疗反应时需关注血红蛋白、血容量及运动心输出量储备的变化。
局限性
- 研究样本量较小(30例),且为单组配对设计,未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sotatercept is an activin ligand trap that markedly improves exercise tolerance in patients with pulmonary arterial hypertension (PAH). OBJECTIVES: The aim of this study was to determine the mechanisms of these functional benefits. METHODS: The effects of 24-week sotatercept treatment on central and peripheral determinants of aerobic capacity, hemodynamic status, cardiovascular function, and oxygen transport in patients with PAH were comprehensively evaluated. Participants underwent blood volume quantification, supine invasive cardiopulmonary exercise testing with simultaneous echocardiography, single-leg exercise catheterization, and exercise femoral venous blood sampling. Participants underwent 7 paired hemodynamic assessments before and after sotatercept (rest, nitric oxide, passive leg raise, 20-W exercise, peak exercise, repeat baseline, and single-leg exercise). RESULTS: Among 30 participants (mean age 49.3 ± 13.5 years, 70% women), sotatercept improved the primary endpoint of peak exercise mean pulmonary artery (PA)/cardiac output (CO) (-2.1 mm Hg/L/min; 95% CI: -3.1 to -1.1 mm Hg/L/min; P = 0.0003). Sotatercept reduced pulmonary vascular resistance (-2.6 WU; 95% CI: -3.0 to -2.2 WU; P < 0.0001), mean PA pressure (-12.5 mm Hg; 95% CI: -13.8 to -11.2 mm Hg; P < 0.0001), and right ventricular (RV) work (-1.1 kg-m/min; 95% CI: -1.4 to -0.9 kg-m/min; P < 0.0001) and improved RV-PA coupling across rest and exercise. Sotatercept reduced systemic congestion, evidenced by decreases in N-terminal pro-B-type natriuretic peptide (P < 0.0001), right atrial pressure (P = 0.04), and blood volume (P < 0.0001). Increases in resting hemoglobin were observed (1.7 g/dL; 95% CI: +1.1 to +2.2 g/dL; P < 0.0001) that were related to reduction in plasma volume (P < 0.0001), as there was no effect on red cell mass (P = 0.12). A decrease in resting CO was observed with sotatercept (-0.58 L/min; 95% CI: -0.85 to -0.32 L/min; P < 0.0001), which appeared to be related to the increase in hemoglobin. Despite lower resting CO, CO reserve with exercise was enhanced (+0.74 L/min; 95% CI: +0.15 to +1.32 L/min; P = 0.015), which was associated with improved aerobic capacity (peak oxygen consumption; r = +0.69; 95% CI: +0.43 to +0.84; P < 0.0001). Single-leg exercise performance also improved after sotatercept. Sotatercept increased both convective oxygen delivery with exertion (P = 0.002; interaction P = 0.018) and peripheral oxygen uptake in skeletal muscle, as evidenced by an increase in arterial-femoral venous O2 content difference across phases (+1.1 mL/dL; 95% CI: +0.7 to +1.4 mL/dL; P < 0.0001). CONCLUSIONS: Sotatercept improves exercise tolerance in patients with PAH through multiple, previously unappreciated mechanisms beyond the pulmonary vasculature, including increased hemoglobin (driven in part by systemic decongestion with hemoconcentration), which along with enhanced RV-PA coupling and CO reserve increases skeletal muscle O2 delivery. The increased O2 delivered occurs despite decreased RV work, with functional benefits further enhanced by augmented skeletal muscle O2 use. (Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension; NCT06409026).
引用
- Reddy YNV, Frantz RP, Miranda WR, et al. Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit. J Am Coll Cardiol. 2026. PMID: 41885673. doi:10.1016/j.jacc.2026.02.5103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。